Last reviewed · How we verify

NCT06261541

Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting

Completed NA Last updated 31 July 2024
What this trial tests

NA trial testing ABLE Exoskeleton in Multiple Sclerosis in 33 participants. Completed in 30 July 2024.

Timeline
8 April 2024
Primary endpoint
30 July 2024
30 July 2024

Quick facts

Lead sponsorABLE Human Motion S.L.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment33
Start date8 April 2024
Primary completion30 July 2024
Estimated completion30 July 2024
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

ABLE Human Motion S.L.

Who can join

Adults 18 to 70, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the study is to validate the safety and performance of the ABLE Exoskeleton device in people with multiple sclerosis during a 10-session gait training program in a clinical setting. Furthermore, the potential effects of the training on walking, and balance function, general health status, user satisfaction, and quality of life will be assessed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ABLE Exoskeleton

Trials testing the same drug.

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other ABLE Human Motion S.L. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06261541.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing